Timothy Franxman is a Rheumatology/Immunology physician. OpenAlex indexes 12 publications with 231 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9800 Shelbyville Rd
Suite #220
Louisville, KY 402232992
Telephone
502-429-8585Provider last certified this registry record 26 May 2021.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202551 payments$20,926openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202528 payments
- Novartis Pharmaceuticals CorporationProgram year202525 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
88.2%Leukotriene Receptor Antagonist39.8%Montelukast Sodium100%Part D≥139 patientsCorticosteroid22.8%Fluticasone Propionate48%Breo Ellipta21%Trelegy Ellipta19%Xhance7%Breztri Aerosphere5%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
5.5%Corticosteroid3.3%Prednisone100%Part D≥33 patientsH2 blocker2.2%Famotidine100%Part D≥13 patientsDermatology
5.2%Interleukin-4 Receptor alpha Antagonist5.2%Dupixent Pen63%Dupixent Syringe37%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Characteristics of Tree Nut Challenges in Tree Nut Allergic and Tree Nut Sensitized Individuals
Journal of Allergy and Clinical Immunology
2016 - The Relationship Between Self-Efficacy, Quality of Life, and Oral Food Challenge
Journal of Allergy and Clinical Immunology
2016 - What affects quality of life among caregivers of food-allergic children?
Annals of Allergy Asthma & Immunology
2014 - Oral Food Challenge and Food Allergy Quality of Life in Caregivers of Children with Food Allergy
The Journal of Allergy and Clinical Immunology In Practice
2014 - Infliximab for Treatment of Granulomatous Disease in Patients with Common Variable Immunodeficiency
Journal of Clinical Immunology
2014
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”